Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $992K fell 61.8% year over year, behind the -39.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 53.4% from the prior quarter. Over 3 fiscal years it compounded at -34.0% a year.

Context

  • Stock-based compensation amounted to 23.0% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -61.8% toward the trailing-twelve-month pace of -39.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$992K-53.4% QoQ
Last fiscal yearDec 2025
$9.08M-26.7% YoY
LTMMar 2026
$7.48M-39.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-61.8%——
1 year-26.7%——
3-year CAGR-34.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.08M USD
Year-over-year change
-26.7%
4-year CAGR
-27.6%

Stock-Based Compensation vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -39.0% is the 9th highest of 11, against a peer median of -16.1%.
  • Stock-based compensation amounts to 21.6% of revenue for SGMO, versus a peer median of 98.2%.
SGMO Competitors
Stock-Based Compensation for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CCCCC4 Therapeutics, Inc.LTM Mar 2026$16.26M USD-43.8%-14.0%46.7%
OABIOmniAb, Inc.LTM Mar 2026$15.02M USD-24.7%-4.8%52.0%
IVVDInvivyd, Inc.LTM Mar 2026$11.51M USD-33.2%-18.7%20.6%
CDXSCodexis, Inc.LTM Mar 2026$8.67M USD-29.5%-12.8%11.1%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$7.48M USD-39.0%-34.0%21.6%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$6.67M USD-45.2%-9.2%210.3%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$6.14M USD+9.4%-6.2%344.3%
IPHAInnate Pharma S.A.FY2025€4.26M EUR+7.9%+0.1%152.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.9M USD-7.5%-5.6%98.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$2.4M USD+50.7%-39.5%123.1%
Peer median (excluding SGMO) —-16.1%-7.7%98.2%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(178.3M)(192.28M)(257.83M)(97.94M)(122.93M)
Depreciation & Amortization17.64M20.56M22.19M9.36M7.6M
Deferred Income Tax2.77M0(6.34M)00
Stock-Based Compensation32.96M31.65M27.36M12.38M9.08M
Change in Working Capital(101.9M)(82.32M)(164.03M)4.51M(4.22M)
Accounts Receivables(789K)2.34M(976K)953K155K
Inventory7.66M0000
Accounts Payables(7.66M)13.35M5.59M(14.17M)2.79M
Other Working Capital(101.11M)(98M)(168.65M)17.72M(7.17M)
Other Non-Cash Items(6.43M)(1.24M)153.8M4.55M13.27M
Operating Cash Flow(233.25M)(223.63M)(224.84M)(67.14M)(97.21M)
Capital Expenditures(23.28M)(20.17M)(21.16M)(267K)(102K)
Acquisitions (Net)(119K)(79.46M)01.95M0
Purchases of Investments(338.16M)(277.39M)(59.55M)00
Sales of Investments609.76M356.85M234.24M35.84M0
Other Investing Activities079.46M000
Investing Cash Flow248.2M59.29M153.53M37.52M(102K)
Debt Repayment00000
Common Stock Issued27.1M84.87M15.11M28.99M74.01M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.76M(209K)(518K)(614K)(3.26M)
Financing Cash Flow32.86M84.66M14.59M28.38M70.75M
Effect of Forex Changes(263K)1.25M1.48M(2.05M)4.09M
Net Change in Cash47.54M(78.43M)(55.24M)(3.29M)(22.47M)
Free Cash Flow(256.53M)(243.8M)(246M)(67.41M)(97.31M)

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.